Stocks
I
MRK I
Apr 25, 2024, 11:45:19 AM
Merck Announces Impressive First-Quarter Financial Results for 2024
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, reported robust financial results for the first quarter of 2024, demonstrating strong growth particularly in its oncology and vaccines sectors. The total worldwide sales reached $15.8 billion, marking a 9% increase from the first quarter of 2023. When adjusted for foreign exchange impacts, the growth rate was an impressive 12%.
Earnings Overview
- GAAP Earnings Per Share (EPS): Increased from $1.11 in Q1 2023 to $1.87 in Q1 2024.
- Non-GAAP EPS: Rose from $1.40 in Q1 2023 to $2.07 in Q1 2024.
- Both GAAP and Non-GAAP EPS include a charge of $0.26 per share due to the acquisition of Harpoon Therapeutics.
Strong Product Sales
- KEYTRUDA: Sales grew by 20% to $6.9 billion, with a 24% increase excluding foreign exchange impacts.
- GARDASIL/GARDASIL 9: Reported a 14% increase to $2.2 billion in sales, and 17% growth excluding foreign exchange impacts.
Strategic Developments
FDA Approvals and Clinical Progress
- WINREVAIR: Received FDA approval for the treatment of adults with Pulmonary Arterial Hypertension (PAH), marking it as a first-in-class treatment.
- Continued progress in other therapeutic areas including oncology, vaccines, and infectious diseases.
Business Expansion
- Completed the acquisition of Harpoon and proposed the acquisition of Elanco’s Aqua business, expanding its pipeline and portfolio.
Full-Year 2024 Financial Outlook
Revised Projections
- Worldwide Sales: Expected to be between $63.1 billion and $64.3 billion.
- Non-GAAP EPS: Forecasted to range from $8.53 to $8.65.
- Both metrics have been adjusted upwards, reflecting strong current performance and positive future expectations.
Key Factors Impacting Outlook
- The outlook includes a negative impact of foreign exchange, primarily due to the devaluation of the Argentine peso, expected to be offset by inflation-related price increases.
- Includes a charge for the acquisition of Harpoon that impacts the EPS forecast.